Table 2 ACS Patient characteristics
Characteristic | Distribution total cohort | Distribution experienced endpoint | Distribution no end-point | p |
|---|---|---|---|---|
Sample size | 407 | 74 | 333 | |
Age | 65 (11.1) | 67.8 (11.8) | 64.5 (10.9) | 0.02 |
Men | 76.9% | 78.1% | 76.6% | 0.79 |
Diabetes Mellitus | 17.2% | 17.8% | 17.1% | 0.88 |
Hypertonia | 43.5% | 52.1% | 41.6% | 0.10 |
Current Smoking | 24.8% | 23.3% | 25.1% | 0.74 |
Mean time to sample (hours) | 38.4 (32.2) | 42.7 (13.7) | 38.2 (6.9) | 0.28 |
Diagnosis | 0.04 | |||
STEMI | 42.5% | 53.4% | 40.1% | 0.79 |
NSTEMI | 35.9% | 35.6% | 35.9% | |
Non-MI | 21.6% | 11.0% | 24.0% | |
Unstable angina | 63,6% | 85.7% | 62,5% | |
Stable angina | 21,6% | 0% | 26.2% | |
Chest pain | 14,8% | 14.3% | 11.2% | |
Troponin T (ng/l) | 2.55 (3.76) | 5.14 (5.25) | 1.98 (3.08) | <0.0000001 |
Concurrent therapy | ||||
Aspirin | 35.1% | 34.2% | 35.3% | 0.79 |
Beta-adrenergic antagonists | 32.4% | 56.2% | 29.9% | 0.05 |
Ca2+-channel antagonists | 17.7% | 19.2% | 17.4% | 0.61 |
Statins | 31.7% | 35.6% | 30.8% | 0.60 |
ACE inhibitors | 17.7% | 26.0% | 15.9% | 0.08 |
Death within 3 months (%) | 1.2% | 6.8% | 0% | 0.000001 |
LVEF | <0.0000001 | |||
>50% | 62.8% | 5.6% | 78.7% | |
40-49% | 17.4% | 5.6% | 21.3% | |
30-39% | 14.5% | 67.6% | 0% | |
<30% | 4.4% | 21.1% | 0% | |
miRNA (ln 2-∆Ct) | ||||
miR-1 | −2.69 (0.99) | −2.58 (1.08) | −2.71 (0.97) | 0.32 |
miR-208b | −4.59 (2.22) | −3.70 (2.38) | −4.78 (2.14) | 0.0001 |
miR-499-5p | −4.77 (1.80) | −4.03 (2.04) | −4.93 (1.71) | 0.00009 |